JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Äbelö, A.
Right arrow Articles by Gabrielsson, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Äbelö, A.
Right arrow Articles by Gabrielsson, J.

Vol. 295, Issue 2, 662-669, November 2000

A Turnover Model of Irreversible Inhibition of Gastric Acid Secretion by Omeprazole in the Dog

Angela Äbelö, Ulf G. Eriksson, Mats O. Karlsson, Håkan Larsson and Johan Gabrielsson

Drug Metabolism and Pharmacokinetics & Bioanalytical Chemistry (A.Ä.), Experimental Medicine (U.G.E.), and Gastrointestinal Pharmacology (H.L.), AstraZeneca R&D Mölndal, Mölndal, Sweden; Department of Pharmacy, Division of Biopharmaceutics and Pharmacokinetics, Biomedical Center, Uppsala University, Uppsala, Sweden (M.O.K.); and Drug Metabolism and Pharmacokinetics, AstraZeneca R&D, Södertälje, Sweden (J.G.)

A turnover model for irreversible inhibition of gastric acid secretion by omeprazole in gastric fistula dogs was developed using data from studies with both short- and long-term measurement periods. In the short-term experiments, after stimulation of acid secretion with histamine, the dogs were infused i.v. with omeprazole and acid secretion was measured for 5 h. Dose and infusion times were varied to produce different concentration-time profiles and schedule dependence in the inhibitory effect of omeprazole was observed. In the long-term experiments, dogs were given single intraduodenal doses, which inhibited the acid secretion for several days. Combining the short-term and long-term data allowed the observation of a biphasic recovery of acid secretion that was described by the turnover model. Second order association rate constants (kome) for the covalent binding of omeprazole to H+,K+-ATPase were estimated to 11 and 3.0 l/µmol/h for the i.v. and intraduodenal experiments, respectively. The apparent turnover rate constant of the enzyme (kout) was 0.013 h-1 and the corresponding half-life of inhibition of acid secretory capacity was 54 h. The potency, calculated as kout over kome, was 4.3 and 1.2 nM for the intraduodenal and i.v. doses, respectively. Allometric scaling of the model resulted in trustworthy predictions for observations previously done in humans. The model predicted a good correlation between maximal inhibitory effect and exposure (area under the plasma concentration curve). The time dependence in this relation was also predicted by the model.


0022-3565/00/2952-0662$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Exp. Biol.Home page
C. M. Wood, A. G. Schultz, R. S. Munger, and P. J. Walsh
Using omeprazole to link the components of the post-prandial alkaline tide in the spiny dogfish, Squalus acanthias
J. Exp. Biol., March 1, 2009; 212(5): 684 - 692.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. E. Mager, E. Wyska, and W. J. Jusko
Diversity of Mechanism-Based Pharmacodynamic Models
Drug Metab. Dispos., May 1, 2003; 31(5): 510 - 518.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.